Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Research output: Contribution to journal › Article
The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||European Journal of Endocrinology|
|Publication status||Published - 2016|